These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 2437293

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
    Riachi NJ, Harik SI, Kalaria RN, Sayre LM.
    J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
    Bradbury AJ, Costall B, Domeney AM, Testa B, Jenner PG, Marsden CD, Naylor RJ.
    Neurosci Lett; 1985 Oct 24; 61(1-2):121-6. PubMed ID: 2417166
    [Abstract] [Full Text] [Related]

  • 5. Comparative toxicity of MPTP, MPP+ and 3,3-dimethyl-MPDP+ to dopaminergic neurons of the rat substantia nigra.
    Sayre LM, Arora PK, Iacofano LA, Harik SI.
    Eur J Pharmacol; 1986 May 13; 124(1-2):171-4. PubMed ID: 3487462
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuropharmacological manipulations with MPTP.
    Barnes NJ, Bradbury AJ, Costall B, Domeney AM, Kelly ME, Naylor RJ.
    J Neural Transm Suppl; 1986 May 13; 20():47-63. PubMed ID: 3091761
    [Abstract] [Full Text] [Related]

  • 9. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse.
    Perry TL, Yong VW, Jones K, Wall RA, Clavier RM, Foulks JG, Wright JM.
    Neurosci Lett; 1985 Aug 05; 58(3):321-6. PubMed ID: 3876525
    [Abstract] [Full Text] [Related]

  • 10. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI, Riachi NJ, Hritz MA, Berridge MS, Sayre LM.
    J Pharmacol Exp Ther; 1993 Aug 05; 266(2):790-5. PubMed ID: 8355208
    [Abstract] [Full Text] [Related]

  • 11. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ.
    N Engl J Med; 1985 May 30; 312(22):1418-21. PubMed ID: 2581135
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Studies on the mechanism of the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Heikkila RE, Nicklas WJ, Duvoisin RC.
    Adv Neurol; 1987 May 30; 45():149-52. PubMed ID: 3103384
    [No Abstract] [Full Text] [Related]

  • 14. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK, Sonsalla PK, Sieber BA, Heikkila RE.
    J Pharmacol Exp Ther; 1989 Jun 30; 249(3):820-8. PubMed ID: 2786564
    [Abstract] [Full Text] [Related]

  • 15. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Chiba K, Kubota E, Miyakawa T, Kato Y, Ishizaki T.
    J Pharmacol Exp Ther; 1988 Sep 30; 246(3):1108-15. PubMed ID: 3262153
    [Abstract] [Full Text] [Related]

  • 16. 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Finnegan KT, Irwin I, Delanney LE, Ricaurte GA, Langston JW.
    J Pharmacol Exp Ther; 1987 Sep 30; 242(3):1144-51. PubMed ID: 3498815
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.
    Youngster SK, Nicklas WJ, Heikkila RE.
    J Pharmacol Exp Ther; 1989 Jun 30; 249(3):829-35. PubMed ID: 2786565
    [Abstract] [Full Text] [Related]

  • 18. Tissue culture model for studying MPTP toxicity to dopamine neurons.
    Mytilineou C, Cohen G.
    Adv Neurol; 1987 Jun 30; 45():145-8. PubMed ID: 3493622
    [No Abstract] [Full Text] [Related]

  • 19. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1).
    Sheng JG, Xu DL, Yu HZ, Xu XR, Tang QM.
    Life Sci; 1987 May 18; 40(20):2007-10. PubMed ID: 2437428
    [Abstract] [Full Text] [Related]

  • 20. The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra.
    Bradbury AJ, Costall B, Domeney AM, Jenner PJ, Marsden CD, Naylor RJ.
    Neurosci Lett; 1986 Jun 18; 67(2):208-12. PubMed ID: 2425303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.